Tandem Diabetes Care (TNDM) Competitors

$14.11 -0.58 (-3.95%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$14.22 +0.11 (+0.74%)

As of 06:35 AM Eastern

TNDM vs. NVST, IRTC, TMDX, LQDA, and LIVN

Should you buy Tandem Diabetes Care stock or one of its competitors? MarketBeat compares Tandem Diabetes Care with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tandem Diabetes Care include Envista (NVST), iRhythm Technologies (IRTC), TransMedics Group (TMDX), Liquidia (LQDA), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.

How does Tandem Diabetes Care compare to Envista?

Envista (NYSE:NVST) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Envista has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

Envista has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72B	1.43	$47M	$0.41	58.38
Tandem Diabetes Care	$1.01B	0.95	-$204.71M	-$1.40	N/A

Envista presently has a consensus price target of $28.83, indicating a potential upside of 20.47%. Tandem Diabetes Care has a consensus price target of $29.89, indicating a potential upside of 111.87%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Tandem Diabetes Care	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.52

Envista has a net margin of 2.41% compared to Tandem Diabetes Care's net margin of -9.20%. Envista's return on equity of 7.11% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%

In the previous week, Tandem Diabetes Care had 4 more articles in the media than Envista. MarketBeat recorded 21 mentions for Tandem Diabetes Care and 17 mentions for Envista. Tandem Diabetes Care's average media sentiment score of 0.99 beat Envista's score of 0.62 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envista	4 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tandem Diabetes Care	10 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Envista beats Tandem Diabetes Care on 8 of the 15 factors compared between the two stocks.

How does Tandem Diabetes Care compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Tandem Diabetes Care (NASDAQ:TNDM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

iRhythm Technologies currently has a consensus price target of $193.38, indicating a potential upside of 68.66%. Tandem Diabetes Care has a consensus price target of $29.89, indicating a potential upside of 111.87%. Given Tandem Diabetes Care's higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Tandem Diabetes Care	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.52

In the previous week, Tandem Diabetes Care had 16 more articles in the media than iRhythm Technologies. MarketBeat recorded 21 mentions for Tandem Diabetes Care and 5 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.47 beat Tandem Diabetes Care's score of 0.99 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tandem Diabetes Care	10 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRhythm Technologies has a net margin of -3.53% compared to Tandem Diabetes Care's net margin of -9.20%. iRhythm Technologies' return on equity of -10.26% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%

iRhythm Technologies has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

iRhythm Technologies has higher earnings, but lower revenue than Tandem Diabetes Care. iRhythm Technologies is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	5.04	-$44.55M	-$0.86	N/A
Tandem Diabetes Care	$1.01B	0.95	-$204.71M	-$1.40	N/A

Summary

iRhythm Technologies beats Tandem Diabetes Care on 9 of the 14 factors compared between the two stocks.

How does Tandem Diabetes Care compare to TransMedics Group?

Tandem Diabetes Care (NASDAQ:TNDM) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Tandem Diabetes Care currently has a consensus price target of $29.89, indicating a potential upside of 111.87%. TransMedics Group has a consensus price target of $135.00, indicating a potential upside of 110.35%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, equities analysts clearly believe Tandem Diabetes Care is more favorable than TransMedics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.52
TransMedics Group	0 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Tandem Diabetes Care had 12 more articles in the media than TransMedics Group. MarketBeat recorded 21 mentions for Tandem Diabetes Care and 9 mentions for TransMedics Group. Tandem Diabetes Care's average media sentiment score of 0.99 beat TransMedics Group's score of 0.15 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	10 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

TransMedics Group has a net margin of 27.04% compared to Tandem Diabetes Care's net margin of -9.20%. TransMedics Group's return on equity of 22.38% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
TransMedics Group	27.04%	22.38%	8.46%

Tandem Diabetes Care has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market. Comparatively, TransMedics Group has a beta of 2.07, indicating that its share price is 107% more volatile than the broader market.

TransMedics Group has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	0.95	-$204.71M	-$1.40	N/A
TransMedics Group	$605.49M	3.66	$190.29M	$4.40	14.59

99.7% of TransMedics Group shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

TransMedics Group beats Tandem Diabetes Care on 10 of the 17 factors compared between the two stocks.

How does Tandem Diabetes Care compare to Liquidia?

Tandem Diabetes Care (NASDAQ:TNDM) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

64.5% of Liquidia shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 25.6% of Liquidia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tandem Diabetes Care has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market. Comparatively, Liquidia has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

In the previous week, Liquidia had 22 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 43 mentions for Liquidia and 21 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 0.99 beat Liquidia's score of 0.56 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	10 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	13 Very Positive mention(s)	5 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Tandem Diabetes Care currently has a consensus price target of $29.89, indicating a potential upside of 111.87%. Liquidia has a consensus price target of $49.33, indicating a potential downside of 14.34%. Given Tandem Diabetes Care's higher possible upside, equities analysts clearly believe Tandem Diabetes Care is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.52
Liquidia	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.92

Liquidia has lower revenue, but higher earnings than Tandem Diabetes Care. Liquidia is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	0.95	-$204.71M	-$1.40	N/A
Liquidia	$158.32M	32.35	-$68.92M	-$0.83	N/A

Liquidia has a net margin of 7.74% compared to Tandem Diabetes Care's net margin of -9.20%. Liquidia's return on equity of 46.82% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
Liquidia	7.74%	46.82%	7.06%

Summary

Liquidia beats Tandem Diabetes Care on 12 of the 17 factors compared between the two stocks.

How does Tandem Diabetes Care compare to LivaNova?

Tandem Diabetes Care (NASDAQ:TNDM) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

97.6% of LivaNova shares are held by institutional investors. 2.1% of Tandem Diabetes Care shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Tandem Diabetes Care has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

In the previous week, Tandem Diabetes Care had 7 more articles in the media than LivaNova. MarketBeat recorded 21 mentions for Tandem Diabetes Care and 14 mentions for LivaNova. Tandem Diabetes Care's average media sentiment score of 0.99 beat LivaNova's score of 0.57 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	10 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Tandem Diabetes Care presently has a consensus price target of $29.89, suggesting a potential upside of 111.87%. LivaNova has a consensus price target of $77.22, suggesting a potential upside of 6.60%. Given Tandem Diabetes Care's higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.52
LivaNova	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70

Tandem Diabetes Care has higher earnings, but lower revenue than LivaNova. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	0.95	-$204.71M	-$1.40	N/A
LivaNova	$1.39B	2.87	-$242.47M	$1.95	37.15

LivaNova has a net margin of 7.48% compared to Tandem Diabetes Care's net margin of -9.20%. LivaNova's return on equity of 16.48% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
LivaNova	7.48%	16.48%	7.59%

Summary

LivaNova beats Tandem Diabetes Care on 9 of the 17 factors compared between the two stocks.

Get Tandem Diabetes Care News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNDM vs. The Competition

Export

Metric	Tandem Diabetes Care	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.01B	$6.90B	$6.30B	$12.20B
Dividend Yield	N/A	1.72%	2.79%	5.30%
P/E Ratio	-10.08	49.93	21.03	25.58
Price / Sales	0.95	39.65	548.94	78.80
Price / Cash	N/A	24.21	42.94	55.34
Price / Book	7.31	6.49	9.84	6.66
Net Income	-$204.71M	$158.34M	$3.55B	$333.63M
7 Day Performance	-23.61%	-1.83%	-0.52%	-0.12%
1 Month Performance	-33.16%	-1.10%	1.21%	3.93%
1 Year Performance	-38.25%	-2.35%	41.24%	36.07%

Tandem Diabetes Care Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNDM Tandem Diabetes Care	2.6302 of 5 stars	$14.11 -3.9%	$29.89 +111.9%	-39.0%	$1.01B	$1.01B	N/A	2,500	Earnings Report Analyst Forecast
NVST Envista	3.4368 of 5 stars	$25.82 -2.0%	$28.25 +9.4%	+28.0%	$4.29B	$2.72B	92.20	12,000	Analyst Downgrade
IRTC iRhythm Technologies	4.4204 of 5 stars	$119.18 -1.3%	$193.38 +62.3%	-18.0%	$3.97B	$747.14M	N/A	2,400	Positive News
TMDX TransMedics Group	4.1946 of 5 stars	$97.08 -2.9%	$152.33 +56.9%	-47.4%	$3.45B	$605.49M	19.81	210
LQDA Liquidia	2.687 of 5 stars	$38.48 +0.9%	$43.44 +12.9%	+260.2%	$3.39B	$158.32M	N/A	50	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNDM) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tandem Diabetes Care (TNDM) Competitors

TNDM vs. NVST, IRTC, TMDX, LQDA, and LIVN

How does Tandem Diabetes Care compare to Envista?

Summary

How does Tandem Diabetes Care compare to iRhythm Technologies?

Summary

How does Tandem Diabetes Care compare to TransMedics Group?

Summary

How does Tandem Diabetes Care compare to Liquidia?

Summary

How does Tandem Diabetes Care compare to LivaNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNDM vs. The Competition

Tandem Diabetes Care Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tandem Diabetes Care (TNDM) Competitors

TNDM vs. NVST, IRTC, TMDX, LQDA, and LIVN

How does Tandem Diabetes Care compare to Envista?

Which has more volatility & risk, NVST or TNDM?

Which has preferable earnings & valuation, NVST or TNDM?

Do analysts prefer NVST or TNDM?

Is NVST or TNDM more profitable?

Does the media refer more to NVST or TNDM?

Summary

How does Tandem Diabetes Care compare to iRhythm Technologies?

Do analysts rate IRTC or TNDM?

Does the media refer more to IRTC or TNDM?

Is IRTC or TNDM more profitable?

Which has more volatility & risk, IRTC or TNDM?

Which has better earnings and valuation, IRTC or TNDM?

Summary

How does Tandem Diabetes Care compare to TransMedics Group?

Do analysts rate TNDM or TMDX?

Does the media refer more to TNDM or TMDX?

Is TNDM or TMDX more profitable?

Which has more volatility & risk, TNDM or TMDX?

Which has preferable valuation & earnings, TNDM or TMDX?

Do insiders and institutionals have more ownership in TNDM or TMDX?

Summary

How does Tandem Diabetes Care compare to Liquidia?

Do insiders and institutionals have more ownership in TNDM or LQDA?

Which has more volatility & risk, TNDM or LQDA?

Does the media refer more to TNDM or LQDA?

Do analysts rate TNDM or LQDA?

Which has preferable valuation & earnings, TNDM or LQDA?

Is TNDM or LQDA more profitable?

Summary

How does Tandem Diabetes Care compare to LivaNova?

Do institutionals and insiders hold more shares of TNDM or LIVN?

Which has more risk and volatility, TNDM or LIVN?

Does the media prefer TNDM or LIVN?

Do analysts prefer TNDM or LIVN?

Which has higher valuation & earnings, TNDM or LIVN?

Is TNDM or LIVN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNDM vs. The Competition

Tandem Diabetes Care Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools